Research Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Evaluating the effectiveness and safety of two consecutive cycles of single embryo transfer versus one cycle of double embryo transfer in infertile women.

Evaluating the effectiveness and safety of two consecutive cycles of single embryo transfer versus one cycle of double embryo transfer in infertile women.

Posted by on Jan 30, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the effectiveness and safety of two consecutive cycles of single embryo transfer (SET) versus one cycle of double embryo transfer (DET) in infertile women. The data showed that two consecutive cycles of SET significantly reduced the rate of multiple births, improved the maternal and neonatal side effects, and showed a...

Read More

Evaluating the effectiveness and safety of mFOLFOXIRI chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer

Evaluating the effectiveness and safety of mFOLFOXIRI chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer

Posted by on Jan 26, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safery of administering modified (m) FOLFOXIRI (folinic acid, fluorouracil, irinotecan, oxaliplatin) chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer (LARC). The results showed that this treatment was safe and improved survival without disease...

Read More

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Posted by on Jan 15, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...

Read More

Can biologic treatments influence the occurrence of infections in patients with rheumatoid arthritis?

Can biologic treatments influence the occurrence of infections in patients with rheumatoid arthritis?

Posted by on Jan 8, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared the occurrence of infections and identified their risk factors in patients with rheumatoid arthritis (RA) that were treated with tofacitinib (Xeljanz) against those given a tumor necrosis factor inhibitor (TNFi). The data showed that serious and non-serious infections were higher in patients that received...

Read More

Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.

Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.

Posted by on Jan 8, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the tolerability and effectiveness of combined therapy using venetoclax (Venclexta) and gilteritinib (Xospata) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with the FLT3 (FMS-related tyrosine kinase 3) mutation. The data showed that a combination of venetoclax and gilteritinib potentially...

Read More

How effective and safe is dapagliflozin as an add-on therapy to insulin in patients with type 1 diabetes?

How effective and safe is dapagliflozin as an add-on therapy to insulin in patients with type 1 diabetes?

Posted by on Jan 8, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the most effective and safe dose of dapagliflozin (Farxiga) as an additional treatment to insulin in patients with type 1 diabetes (T1D). The authors concluded that 10 mg of dapagliflozin as an add-on to insulin treatment resulted in improved blood glucose (sugar) control, reduced insulin dosage, and body...

Read More

Evaluating the safety and effectiveness of FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of metastatic colorectal cancer

Evaluating the safety and effectiveness of FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of metastatic colorectal cancer

Posted by on Jan 8, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (Avastin) with or without atezolizumab (Tecentriq) on the outcomes of patients with metastatic (m) colorectal cancer (CRC). The study showed that adding atezolizumab to FOLFOXIRI plus...

Read More

Evaluating the effectiveness and safety of ivabradine in combination with beta-blockers in patients with stable angina.

Evaluating the effectiveness and safety of ivabradine in combination with beta-blockers in patients with stable angina.

Posted by on Jan 8, 2023 in Coronary artery disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ivabradine (Procoralan) in combination with beta-blockers in patients with stable angina. The data showed that the combination of ivabradine plus beta-blocker therapy effectively reduced heart rate, angina symptoms, and the use of short-acting nitrates from the first month of treatment...

Read More

Evaluating the optimal treatment regimens given before and after surgery in improving survival outcomes in patients with HER2-positive breast cancer.

Evaluating the optimal treatment regimens given before and after surgery in improving survival outcomes in patients with HER2-positive breast cancer.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the optimal treatment regimens given before and after surgery in terms of improving the survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). The data showed that chemotherapy plus trastuzumab (Herceptin) and pertuzumab (Perjeta) was the best treatment...

Read More

Evaluating the effects of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertile women with PCOS.

Evaluating the effects of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertile women with PCOS.

Posted by on Jan 8, 2023 in Infertility | 0 comments

In a nutshell This study compared the effects of metformin (Glucophage) and exenatide (Byetta) on pregnancy rate and pregnancy outcomes in overweight or obese infertile women with polycystic ovary syndrome (PCOS). The data showed that 12 weeks of exenatide treatment before pregnancy improved spontaneous pregnancy in these women. Some background...

Read More

Evaluating the effectiveness and safety of transanal versus laparoscopic total mesorectal resection for the treatment of patients with rectal cancer.

Evaluating the effectiveness and safety of transanal versus laparoscopic total mesorectal resection for the treatment of patients with rectal cancer.

Posted by on Jan 8, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of transanal (ta) versus laparoscopic (lap) total mesorectal resection (TME) for the treatment of patients with stage I-III rectal cancer (RC). The data showed that experienced surgeons can safely perform taTME in these patients. Some background Rectal cancer (RC) is one of the most...

Read More

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Read More